Dale Terasaki, MD, MPH

Professional Titles

• Attending physician, Inpatient addiction consult service
• Faculty member, Addiction medicine fellowship
• Faculty member, Addiction psychiatry fellowship

Recognitions

• Colorado Health Service Corps, Colorado Department of Public Health & Environment (2020)
  3-year service commitment to substance use disorder treatment in high need area
• 5280 Top Doc for Addiction Medicine, 5280 Magazine (2020)

Research Interests

Publications

• Terasaki D & Klie K. Tramadol withdrawal in setting of buprenorphine induction, a case report. Journal of Addiction Medicine. May/Jun 2020;14(3):264-266.
• Terasaki, D. (2019) Clinical Harm Reduction for Addiction: A Strategy Internists Can (And Do) Embrace. SGIM Forum 42 (9): 5, 9.
• Terasaki D, Smith C, Calcaterra SL. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Pharmacotherapy. 2019 Oct;39(10):1023-1029. PubMed PMID: 31348544
• Mortaji P, Terasaki D, Moo-Young J. Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries. J Gen Intern Med. 2021 Aug;36(8):2448-2451. PubMed PMID: 33782885
• Terasaki D (2021). Methadone disposition on a Friday. SGIM Forum 44 (8): 8, 12.
• Terasaki D. Cardiovascular medications on discharge for patients with chest pain and concurrent cocaine use. Am J Emerg Med. 2022 Mar 4;. doi: 10.1016/j.ajem.2022.02.060. [Epub ahead of print] PubMed PMID: 35279327.
• Terasaki D, Shaffie R, Loh R (2022). Characteristics of hospitalized patients whose substance use increased amid the impacts of COVID-19. The Hospitalist. Online publication. March 3, 2022. Available at: https://www.the-hospitalist.org/
• Terasaki D, Loh R, Cornell A, Taub J, Thurstone C. Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates. Addict Sci Clin Pract. 2022 Nov 22;17(1):64. PubMed PMID: 36419181
• Terasaki D. Self-reported Past Experiences With Naltrexone and Attitudes Toward Daily Adherence Among High-utilization Patients With Alcohol Use Disorder. J Addict Med. 2023 Jan 17. [Epub ahead of print] PubMed PMID: 36728042
• Terasaki D, Brady J. Severe, Nondelirium Agitation as an Underreported Characteristic of Precipitated Fentanyl Withdrawal: A Case Report. J Addict Med. 2023 Jan-Feb 01;17(1):111-113. PubMed PMID: 35914120
• Terasaki D. Cardiovascular medications on discharge for patients with chest pain and concurrent cocaine use. Am J Emerg Med. 2022 Aug;58:315-316. PubMed PMID: 35279327
• Lyden J, Loh R, Braun H, Terasaki D. Characterizing safer drinking strategies among hospitalized adults with severe alcohol use disorder; a cross-sectional secondary analysis. J Addict Dis. 2023 Nov 9;:1-5. [Epub ahead of print] PubMed PMID: 37946362
• Terasaki D, Hanratty R, Thurstone C. More than MAT: lesser-known benefits of an inpatient addiction consult service. Hosp Pract (1995). 2023 Aug;51(3):107-109. PubMed PMID: 37314327
• Terasaki D. Self-reported Past Experiences With Naltrexone and Attitudes Toward Daily Adherence Among High-utilization Patients With Alcohol Use Disorder. J Addict Med. 2023 May-Jun 01;17(3):371-372. PubMed PMID: 37267196
• Deaney M, Terasaki D. Intramuscular, extended-release naltrexone inadvertently administered in the deltoid muscle: A case report. J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1245-1248. PubMed PMID: 37207707
• Terasaki D, Kulick B, Calcaterra S, Ray L. Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat. Addiction. 2023 Jul;118(7):1198-1200. PubMed PMID: 36967706

Professional Memberships

• American Society of Addiction Medicine, Member

Practice Locations

• Denver Health Medical Center

Specialty Information

• Internal Medicine, Board Certification (2018)
• Addiction Medicine, Board Certification (2019)